Terms ending in 2039
Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,286,472 | Biopharmaceutical Compositions and Methods for Pediatric Patients In force · High confidence | GlaxoSmithKline Intellectual Property (No.2) Limited | In force | High confidence | |
| US 11,015,180 | Carboxyesterase Polypeptides for Amide Coupling In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,576,089 | Platelet Count-Agnostic Methods of Treating Myelofibrosis In force · Low confidence | GlaxoSmithKline LLC | In force | Low confidence | |
| US D1,042,109 | Package In force · High confidence | Haleon UK IP Limited | In force | High confidence | |
| US 12,686,702 | Methods for Purifying Antibodies In force · High confidence | GlaxoSmithKline Intellectual Property Development Limited | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by GlaxoSmithKline LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.